Lower-risk myelodysplastic syndromes (MDS) patients often live many years on transfusion support - accumulating iron that can compound organ dysfunction. Deferasirox can help - but careful patient selection is essential.
1. Who Benefits? #
- Lower-risk MDS by IPSS / IPSS-R (Low, Int-1 / Very Low, Low, Intermediate)
- Transfusion-dependent (cumulative >= 20-30 units, ferritin persistently > 1000-2500 ng/mL)
- Expected survival sufficient to benefit (typically >= 1-2 years)
- Adequate renal and hepatic function
2. Who May Not Benefit? #
- High-risk MDS with short expected survival
- Severe baseline cytopenias or organ dysfunction
- Patients with CrCl < 60 mL/min
3. Starting Dose #
MDS patients are typically started on lower doses than thalassemia - e.g. 10-20 mg/kg/day dispersible. The 100 mg and 125 mg unit sizes of DEFRATAJ are particularly useful for careful titration.
4. Monitoring Intensity #
- CBC weekly during initiation (cytopenia can worsen)
- Serum creatinine and electrolytes weekly x 4, then monthly
- Liver function tests monthly
- Serum ferritin monthly (trend > single values)
- Urinalysis for proteinuria monthly
5. Known Serious Risks in MDS #
MDS patients are at higher risk of:
- Renal dysfunction (older age, comorbidities)
- GI hemorrhage (NSAIDs, anticoagulants often concurrent)
- Cytopenia worsening
Severe cutaneous reactions (SJS / TEN / DRESS) - always a class concern - warrant immediate discontinuation if suspected.
6. Pre-Transplant Iron Reduction #
MDS patients considered for allogeneic stem-cell transplant with high pre-transplant iron loads may benefit from chelation - high iron burden is associated with worse transplant outcomes.
7. DEFRATAJ in MDS Programmes #
DEFRATAJ is supplied in five strengths supporting careful MDS titration. See MDS page for clinical detail and DEFRATAJ 100 mg for the fine-titration unit.